Clearmind Medicine Inc. announced on February 3, 2026 that its proprietary MEAI compound has been incorporated into the Expanding Veterans’ Access to Emerging Treatments Act (H.R. 7091). The bill, introduced on January 15, 2026, directs the Department of Veterans Affairs to establish investigational research and extended‑access programs for emerging therapies, explicitly listing MEAI among the covered treatments.
The legislation targets veterans with alcohol use disorder, PTSD, and other conditions that lack effective pharmacologic options. By naming MEAI in federal law, the company gains a potential pathway to participate in VA‑supported clinical trials and expanded‑access protocols, which could accelerate regulatory approval and broaden market reach for the drug.
H.R. 7091 has been referred to the House Committee on Veterans’ Affairs and has not yet been enacted. The bill’s current status means the inclusion of MEAI is a forward‑looking opportunity rather than an immediate benefit, but it signals congressional support for the therapy and sets the stage for future VA engagement.
Clearmind remains a clinical‑stage biotech with no revenue and an earnings‑per‑share of –$30.75, reflecting heavy investment in research and development. The company’s market capitalization is approximately $3.35 million. The MEAI inclusion is therefore a strategic milestone that could unlock federal resources and a sizable veteran patient population, potentially transforming the company’s growth prospects.
Following the announcement, Clearmind’s stock rose 7.17%, peaking at a 15.3% increase during the session. Investors viewed the legislative development as a significant step toward VA‑backed trials and expanded‑access programs, underscoring the company’s potential to address unmet needs in alcohol use disorder and PTSD. CEO Adi Zuloff‑Shani said the bill “represents a crucial advancement for veterans struggling with alcoholism and PTSD, and it opens a new avenue for MEAI to reach those in need.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.